<p>Live Oak Private Wealth LLC 在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在輝瑞公司（NYSE:PFE - 免費報告）的持股減少了 92.5%。該公司在季度內出售了 216,868 股後，持有 17,627 股生物製藥公司的股票。Live Oak Private Wealth LLC 在輝瑞的持股在最近的報告期末價值為 449,000 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
</ul>
<p>其他幾家對沖基金和機構投資者也買賣了 PFE 的股票。Capital Advisory Group Advisory Services LLC 在第二季度將其在輝瑞的持股增加了 2.9%。Capital Advisory Group Advisory Services LLC 現在持有 13,542 股生物製藥公司的股票，價值 328,000 美元，此前在該期間內又購買了 388 股。Citizens National Bank Trust Department 在第二季度將其在輝瑞的持股增加了 0.9%。Citizens National Bank Trust Department 現在持有 46,103 股生物製藥公司的股票，價值 1,118,000 美元，此前在該期間內又購買了 395 股。Peak Asset Management LLC 在第二季度將其在輝瑞的持股增加了 1.4%。Peak Asset Management LLC 現在持有 28,768 股生物製藥公司的股票，價值 697,000 美元，此前在上個季度又購買了 402 股。Able Wealth Management LLC 在第二季度將其在輝瑞的持股增加了 2.0%。Able Wealth Management LLC 現在持有 21,128 股生物製藥公司的股票，價值 512,000 美元，此前在該期間內又購買了 413 股。最後，Boltwood Capital Management 在第三季度將其在輝瑞的持股增加了 0.7%。Boltwood Capital Management 現在持有 58,274 股生物製藥公司的股票，價值 1,485,000 美元，此前在上個季度又購買了 420 股。機構投資者和對沖基金持有該公司 68.36% 的股票。</p>
<h2>分析師設定新目標價</h2>
<p>幾位研究分析師最近對該股票發佈了報告。Scotiabank 在 11 月 13 日的研究報告中開始覆蓋輝瑞的股票。他們對該股票設定了 “行業表現優於大盤” 的評級和 30.00 美元的目標價。美國銀行在 12 月 15 日的報告中將輝瑞的目標價從 29.00 美元下調至 28.00 美元，並對該公司設定了 “中性” 評級。Wolfe Research 在 12 月 17 日的研究報告中對輝瑞設定了 24.00 美元的目標價，並給予該股票 “表現不佳” 的評級。BMO Capital Markets 在 12 月 10 日的研究報告中重申了輝瑞的 “表現優於大盤” 評級。最後，Wall Street Zen 在 9 月 28 日的研究報告中將輝瑞的評級從 “買入” 下調至 “持有”。兩位股票研究分析師給予該股票 “強烈買入” 評級，四位給予 “買入” 評級，十二位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，輝瑞的平均評級為 “持有”，平均目標價為 28.06 美元。</p>
<ul>
<li>輝瑞加大對減肥藥物的投資</li>
</ul>
<p><strong>查看我們關於 PFE 的最新研究報告</strong></p>
<h2>輝瑞價格表現</h2>
<p>輝瑞（NYSE PFE）週一開盤價為 25.10 美元。該公司的市值為 1426.8 億美元，市盈率為 14.59，貝塔值為 0.46。該公司的速動比率為 0.97，流動比率為 1.28，債務與股本比率為 0.62。該股票的 50 日移動平均價格為 25.16 美元，200 日移動平均價格為 24.89 美元。輝瑞公司的 12 個月低點為 20.92 美元，12 個月高點為 27.69 美元。</p>
<ul>
<li>HIMS 的股價波動不定。投資者應該入場嗎？</li>
</ul>
<p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 11 月 4 日發佈了季度財報。這家生物製藥公司報告季度每股收益為 0.87 美元，超出分析師一致預期的 0.79 美元，超出幅度為 0.08 美元。該業務的季度收入為 166.5 億美元，而分析師預期為 169.4 億美元。輝瑞的股本回報率為 20.17%，淨利潤率為 15.65%。輝瑞已將其 2025 財年的指導目標設定為每股收益 3.000-3.150 美元。平均而言，股票分析師預計輝瑞公司本年度每股收益為 2.95 美元。</p>
<h2>輝瑞分紅公告</h2>
<p>該公司最近還宣佈了一項季度分紅，將於 3 月 6 日（星期五）支付。1 月 23 日（星期五）的登記投資者將獲得 0.43 美元的分紅。這相當於年化 1.72 美元的分紅和 6.9% 的分紅收益率。該分紅的除息日為 1 月 23 日（星期五）。輝瑞的派息比率為 100.00%。</p>
<h2>輝瑞簡介</h2>
<p>（免費報告）</p>
<p>輝瑞公司 NYSE: PFE 是一家總部位於紐約市的跨國生物製藥公司。該公司成立於 1849 年，由查爾斯·輝瑞和查爾斯·厄哈特創立，專注於研究、開發、生產和商業化廣泛的人類健康藥物和疫苗。其活動涵蓋發現研究、臨牀開發、監管事務、生產和多個治療領域的全球商業分銷。</p>
<p>輝瑞的產品組合和管道涵蓋腫瘤學、免疫學、心臟病學、內分泌學、罕見疾病、醫院急救和抗感染藥物，以及相當可觀的疫苗業務。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比輝瑞更好</li>
<li>請勿刪除，立即閲讀</li>
<li>富人如何退休</li>
<li>投資者警報：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>100 萬美元在退休中能維持多久？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
<p><strong>想看看其他對沖基金持有的 PFE 嗎？</strong> 訪問 HoldingsChannel.com 獲取輝瑞公司（NYSE:PFE - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
<p>在考慮輝瑞之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
<p>雖然輝瑞目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

輝瑞

<p>Live Oak Private Wealth LLC 在第三季度大幅減少了對輝瑞公司的持股，減持幅度達到 92.5%，目前持有 17,627 股，市值為 449,000 美元。其他機構投資者也對輝瑞進行了倉位調整。分析師對該股票的評級褒貶不一，平均目標價為 28.06 美元。輝瑞的股票開盤價為 25.10 美元，市值為 1,426.8 億美元。該公司報告上個季度每股收益為 0.87 美元，超出預期，並宣佈將於 3 月 6 日支付每股 0.43 美元的季度股息</p>

<p>Live Oak Private Wealth LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 92.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 17,627 shares of the biopharmaceutical company's stock after selling 216,868 shares during the quarter. Live Oak Private Wealth LLC's holdings in Pfizer were worth $449,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Live Oak Private Wealth LLC 在最近向證券交易委員會提交的 13F 表格中表示，在第三季度將其在輝瑞公司（NYSE:PFE - 免費報告）的持股減少了 92.5%。該公司在季度內出售了 216,868 股後，持有 17,627 股生物製藥公司的股票。Live Oak Private Wealth LLC 在輝瑞的持股在最近的報告期末價值為 449,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 12/15 - 12/19</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Capital Advisory Group Advisory Services LLC lifted its stake in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after purchasing an additional 388 shares during the period. Citizens National Bank Trust Department lifted its stake in Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after buying an additional 395 shares during the period. Peak Asset Management LLC boosted its holdings in shares of Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock worth $697,000 after buying an additional 402 shares in the last quarter. Able Wealth Management LLC grew its position in shares of Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock worth $512,000 after buying an additional 413 shares during the period. Finally, Boltwood Capital Management increased its stake in shares of Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company's stock valued at $1,485,000 after acquiring an additional 420 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者也買賣了 PFE 的股票。Capital Advisory Group Advisory Services LLC 在第二季度將其在輝瑞的持股增加了 2.9%。Capital Advisory Group Advisory Services LLC 現在持有 13,542 股生物製藥公司的股票，價值 328,000 美元，此前在該期間內又購買了 388 股。Citizens National Bank Trust Department 在第二季度將其在輝瑞的持股增加了 0.9%。Citizens National Bank Trust Department 現在持有 46,103 股生物製藥公司的股票，價值 1,118,000 美元，此前在該期間內又購買了 395 股。Peak Asset Management LLC 在第二季度將其在輝瑞的持股增加了 1.4%。Peak Asset Management LLC 現在持有 28,768 股生物製藥公司的股票，價值 697,000 美元，此前在上個季度又購買了 402 股。Able Wealth Management LLC 在第二季度將其在輝瑞的持股增加了 2.0%。Able Wealth Management LLC 現在持有 21,128 股生物製藥公司的股票，價值 512,000 美元，此前在該期間內又購買了 413 股。最後，Boltwood Capital Management 在第三季度將其在輝瑞的持股增加了 0.7%。Boltwood Capital Management 現在持有 58,274 股生物製藥公司的股票，價值 1,485,000 美元，此前在上個季度又購買了 420 股。機構投資者和對沖基金持有該公司 68.36% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several research analysts recently issued reports on the stock. Scotiabank assumed coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $30.00 target price on the stock. Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a &#34;neutral&#34; rating for the company in a report on Monday, December 15th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an &#34;underperform&#34; rating in a research report on Wednesday, December 17th. BMO Capital Markets reaffirmed an &#34;outperform&#34; rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Wall Street Zen downgraded Pfizer from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pfizer has an average rating of &#34;Hold&#34; and an average target price of $28.06.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該股票發佈了報告。Scotiabank 在 11 月 13 日的研究報告中開始覆蓋輝瑞的股票。他們對該股票設定了 “行業表現優於大盤” 的評級和 30.00 美元的目標價。美國銀行在 12 月 15 日的報告中將輝瑞的目標價從 29.00 美元下調至 28.00 美元，並對該公司設定了 “中性” 評級。Wolfe Research 在 12 月 17 日的研究報告中對輝瑞設定了 24.00 美元的目標價，並給予該股票 “表現不佳” 的評級。BMO Capital Markets 在 12 月 10 日的研究報告中重申了輝瑞的 “表現優於大盤” 評級。最後，Wall Street Zen 在 9 月 28 日的研究報告中將輝瑞的評級從 “買入” 下調至 “持有”。兩位股票研究分析師給予該股票 “強烈買入” 評級，四位給予 “買入” 評級，十二位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，輝瑞的平均評級為 “持有”，平均目標價為 28.06 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>輝瑞加大對減肥藥物的投資</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on PFE</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 PFE 的最新研究報告</strong></p>
</div><h2>Pfizer Price Performance</h2>
<div class="lb-trans"><h2>輝瑞價格表現</h2>
</div><p>Shares of NYSE PFE opened at $25.10 on Monday. The company has a market capitalization of $142.68 billion, a PE ratio of 14.59 and a beta of 0.46. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The stock's 50 day moving average price is $25.16 and its 200-day moving average price is $24.89. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.</p>
<div class="lb-trans"><p>輝瑞（NYSE PFE）週一開盤價為 25.10 美元。該公司的市值為 1426.8 億美元，市盈率為 14.59，貝塔值為 0.46。該公司的速動比率為 0.97，流動比率為 1.28，債務與股本比率為 0.62。該股票的 50 日移動平均價格為 25.16 美元，200 日移動平均價格為 24.89 美元。輝瑞公司的 12 個月低點為 20.92 美元，12 個月高點為 27.69 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股價波動不定。投資者應該入場嗎？</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>輝瑞（NYSE:PFE - 獲取免費報告）最近在 11 月 4 日發佈了季度財報。這家生物製藥公司報告季度每股收益為 0.87 美元，超出分析師一致預期的 0.79 美元，超出幅度為 0.08 美元。該業務的季度收入為 166.5 億美元，而分析師預期為 169.4 億美元。輝瑞的股本回報率為 20.17%，淨利潤率為 15.65%。輝瑞已將其 2025 財年的指導目標設定為每股收益 3.000-3.150 美元。平均而言，股票分析師預計輝瑞公司本年度每股收益為 2.95 美元。</p>
</div><h2>Pfizer Dividend Announcement</h2>
<div class="lb-trans"><h2>輝瑞分紅公告</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer's payout ratio is 100.00%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 3 月 6 日（星期五）支付。1 月 23 日（星期五）的登記投資者將獲得 0.43 美元的分紅。這相當於年化 1.72 美元的分紅和 6.9% 的分紅收益率。該分紅的除息日為 1 月 23 日（星期五）。輝瑞的派息比率為 100.00%。</p>
</div><h2>Pfizer Profile</h2>
<div class="lb-trans"><h2>輝瑞簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>輝瑞公司 NYSE: PFE 是一家總部位於紐約市的跨國生物製藥公司。該公司成立於 1849 年，由查爾斯·輝瑞和查爾斯·厄哈特創立，專注於研究、開發、生產和商業化廣泛的人類健康藥物和疫苗。其活動涵蓋發現研究、臨牀開發、監管事務、生產和多個治療領域的全球商業分銷。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>輝瑞的產品組合和管道涵蓋腫瘤學、免疫學、心臟病學、內分泌學、罕見疾病、醫院急救和抗感染藥物，以及相當可觀的疫苗業務。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比輝瑞更好</li>
<li>請勿刪除，立即閲讀</li>
<li>富人如何退休</li>
<li>投資者警報：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>100 萬美元在退休中能維持多久？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 PFE 嗎？</strong> 訪問 HoldingsChannel.com 獲取輝瑞公司（NYSE:PFE - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在輝瑞嗎？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮輝瑞之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而輝瑞並不在名單上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然輝瑞目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Live Oak Private Wealth LLC Has $449,000 Stake in Pfizer Inc. $PFE

- Live Oak Private Wealth LLC 在第三季度將對輝瑞公司的持股減少 92.5%。  
- 其持倉在近期報告結束時為 17,627 股，價值約 449,000 美元。  
- 機構投資者目前持有輝瑞股票的 68.36%。

Live Oak Private Wealth LLC 持有輝瑞公司價值 44.9 萬美元的股份